Tissue Analysis After Tumor Ablation for Liver Metastases Leading to Immediate Retreatment

Launched by MEMORIAL SLOAN KETTERING CANCER CENTER · Oct 28, 2019

Keywords

ClinConnect Summary

This clinical trial is looking at how doctors can better understand liver cancer that has spread from other parts of the body. After a procedure to remove tumors in the liver, the researchers will take small samples of the remaining tissue to check for any living cancer cells. By analyzing these samples, the study aims to find out if they can identify the best next steps for treating the cancer. It’s important to know that while these needle biopsies can provide valuable information, they may also have some side effects.

To participate in this trial, you must be between 65 and 74 years old and have liver metastases from different types of cancer. You should have stable liver disease and not have too many tumors in your liver or other parts of your body. If you join the study, you’ll undergo a biopsy after your tumor ablation, and the results could help guide your future treatment. This trial is currently recruiting participants, and everyone is welcome regardless of gender.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Diagnosis of liver metastases from various primary tumors
• • Confined liver disease or limited extrahepatic disease stable/controlled for at least 4 months (extrahepatic disease amenable to treatment is allowed)
• • Lesions of ≤3 cm in maximum diameter
• • At least one FDG-avid lesion to be treated\*\*\*
• • INR \< 1.5\*
• • Platelet count ≥ 50,000
• Exclusion Criteria:
• • Age \< 18
• • Less than 5 mm distance to a structure (GI or biliary tract), that cannot be protected from ablation injury with technical modifications such as hydro or air dissection
• • INR \> 1.5 that cannot be corrected with fresh frozen plasma \*\*
• • Platelet count of \<50,000 that cannot be corrected with transfusion
• • More than 3 tumors in the liver
• • More than 5 tumors of extrahepatic disease (including mediastinal nodes and pulmonary nodules, abdominal or other lymph nodes, and bone metastasis)
• • Presence of any peritoneal Carcinomatosis
• • For patients on Coumadin, general clinical guidelines for IR ablation will be followed.
• • For patients with no FDG-PET avid tumors aim 2 of the protocol will not be assessed